# Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease

> **NCT04335786** · PHASE4 · TERMINATED · sponsor: **Radboud University Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome
- SARS-CoV-2
- COVID
- COVID-19
- Severe Acute Respiratory Syndrome

## Interventions

- **DRUG:** Valsartan (Diovan)
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04335786
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-17
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-25
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335786, "Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04335786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*